Originally published by Zymewire on 09/28/2014.
With Coherus Biosciences’ $86 Million IPO announced last week, we wanted to take a closer look at the companies that stand to benefit the most from the upcoming injection of capital. On the contract research side, Medpace appears to be in a strategic position to block further CRO’s from getting the biosimilar study business (see graphic). The contract manufacturing equation is more diverse with Cook, KBI, Rentschler, and Catalent all getting a piece of the action. Two fill finish opportunities still exist as of the time of this blog post. Check out the graphic for the the full breakdown.